Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for Medical Oncology Congress 2024, affect treatment strategies for patients with non ...

We have seen a number of dynamic changes in MDS over the last few years, and integrating them into our treatment paradigm will impact our approach, and perhaps offer a glimpse into the future." ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...